Back to Companies
Akari Therapeutics Plc
AKTXNasdaqCIK: 0001541157
Recent Form 4 activity at Akari Therapeutics Plc (AKTX) spans 13 filings across 7 insiders (all of them on the buy side). Purchases total $19.5K against $0 in sales — heavily weighted toward buying, for a net purchase of $19.5K. Huh Hoyoung (Director, 10% Owner) is the most active by dollar volume, and the single largest transaction was $1.4M by Huh Hoyoung. All figures are drawn from official SEC Form 3, 4, and 5 disclosures and update as new filings arrive.
Total Volume
$3.2M
Purchases
$19.5K
Sales
$0
Unique Insiders
7
Recent Insider Trades
13 loaded
| Jul 17 | AKTX Akari Therapeutics Plc | Patel Samir Rashmikant | Director, 10% Owner | Exercise | $19.4K |
| Jun 25 | AKTX Akari Therapeutics Plc | Farag Kameel D. | Interim CFO | Grant | $105.0K |
| Jun 25 | AKTX Akari Therapeutics Plc | Gaslightwala Abizer | CEO, Director | Award | $253.2K |
| Dec 18 | AKTX Akari Therapeutics Plc | Bazemore Robert B | Director | Other | $60.1K |
| Dec 18 | AKTX Akari Therapeutics Plc | Patel Samir Rashmikant | Director, 10% Owner | Other | $330.3K |
| Dec 18 | AKTX Akari Therapeutics Plc | Prudo-Chlebosz Raymond | Director | Other | $390.4K |
| Dec 18 | AKTX Akari Therapeutics Plc | Patel Sandip I | Director | Other | $156.1K |
| Dec 18 | AKTX Akari Therapeutics Plc | Gaslightwala Abizer | CEO, Director | Other | $420.4K |
| Dec 18 | AKTX Akari Therapeutics Plc | Farag Kameel D. | Interim CFO | Other | $9.6K |
| Dec 18 | AKTX Akari Therapeutics Plc | Huh Hoyoung | Director, 10% Owner | Other | $1.4M |
| Oct 24 | AKTX Akari Therapeutics Plc | Farag Kameel D. | Interim CFO | Other | $0 |
| Oct 24 | AKTX Akari Therapeutics Plc | Farag Kameel D. | Interim CFO | Grant | $4.6K |
| Aug 29 | AKTX Akari Therapeutics Plc | Gaslightwala Abizer | CEO, Director | Buy | $19.5K |
13 filings